LifeMD

LFMD

Market cap $139M

LifeMD remains a deeply undervalued telehealth stock, now trading with significant pessimism priced in after a 55% decline. LFMD's business model faces risks from slowing growth, legal issues, competition, and a disappointing WorkSimpli sale, but the fundamental story remains intact. Preferred shares yield just under 10% and offer lower risk, but I favor the common stock for its substantial upside potential at current prices.

NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, announces that it will report financial results for the three and 12 months ended December 31, 2025, after the close of the U.S. financial markets on March 9, 2026, and will host a conference call beginning at 4:30 p.m. Eastern time.

LifeMD is rated a buy with an FY 2026 target price of ~$6, implying over 85% upside from current levels. LFMD's shift to a pure-play telehealth model, divesting WorkSimpli, and integrating in-house pharmacy capabilities are expected to drive growth and margin expansion. Regulatory approval for 503-A compounding pharmacy and the Novo Nordisk Wegovy partnership are highlighted as key catalysts for profitability and differentiation.

NEW YORK, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of LifeMD, Inc. (NASDAQ: LFMD) breached their fiduciary duties to shareholders.

New York, New York--(Newsfile Corp. - January 22, 2026) - Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of LifeMD, Inc. (NASDAQ: LFMD)  breached their fiduciary duties to shareholders. According to a federal securities lawsuit, Insiders at LifeMD caused the company to misrepresent or fail to disclose that: (1) LifeMD's competitive position was materially overstated; (2) raising LifeMD's 2025 guidance was reckless because rising customer acquisition costs in LifeMD's RexMD segment, as well as for customer acquisition costs related to the sale of drugs designed to treat obesity, including Wegovy and Zepbound had not properly been accounted for; and (3) as a result, statements about LifeMD's business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.

NEW YORK, Jan. 06, 2026 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care and pharmacy services, today announced the closing of a new senior secured revolving credit facility (“RCF”) with Citizens Bank, N.A. (“Citizens”). The facility has a maturity date of January 2, 2029 and provides for up to $50 million of total availability consisting of $30 million of committed availability with an additional accordion option of up to $20 million. As of closing, no balance was drawn on the RCF as the Company believes its cash on hand and expected cash flow are sufficient to fund its organic growth initiatives.

Adds first and only FDA‑approved oral GLP‑1 to its virtual weight management offering, expanding access to affordable, branded treatment options Adds first and only FDA‑approved oral GLP‑1 to its virtual weight management offering, expanding access to affordable, branded treatment options

NEW YORK, Dec. 26, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services and pharmacy solutions, today announced that its Board of Directors has authorized a cash dividend to holders of the Company's 8.875% Series A Cumulative Perpetual Preferred Stock (Nasdaq: LFMDP) equal to $0.5546875 per share. The preferred dividend will be paid on January 15, 2026, to holders of record at the close of business on January 5, 2026.

NEW YORK, Nov. 24, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services and pharmacy solutions, today announced it has been recognized on both the 2025 Deloitte Technology Fast 500™ and the inaugural TIME's America's Growth Leaders of 2026 lists. These distinguished awards reflect LifeMD's continued revenue growth, financial stability, and emerging leadership position in the health technology sector.

TDOC and LFMD face contrasting paths as telehealth demand climbs, with fundamentals and growth plans shaping which stock stands out.